As basic research on new targets for rheumatoid arthritis (RA) treatment continues, novel therapies move through phase II trials.
Arthritis
The Janus kinase ( JAK) molecule is an immunomodulating signal transduction agent, which has emerged as a new target for rheumatoid arthritis (RA) research.
During the past decade, changes in the treatment of rheumatoid arthritis (RA) have been accumulating faster than treatment experience can be evaluated.
Despite decades of investigation, the causes of rheumatoid arthritis (RA) have remained elusive.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
